A first of its kind bispecific antibody, ivonescimab, combined with chemotherapy has shown promising early results in a phase 2 trial for patients with advanced triple negative breast cancer. The treatment targets both PD 1 and vascular endothelial growth factor, achieving encouraging objective response rates in previously untreated patients. Researchers now plan to advance the therapy to a larger phase 3 trial to confirm its efficacy and safety in this hard to treat cancer subtype.
Triple negative breast cancer (TNBC) remains one of the most aggressive and difficult to treat forms of breast cancer, with limited therapeutic options for patients with advanced disease. A new phase 2 clinical trial, published in Nature Medicine, has evaluated ivonescimab, a bispecific antibody that simultaneously targets PD 1 and vascular endothelial growth factor (VEGF), in combination with chemotherapy. The trial included patients with treatment naive, locally advanced unresectable or metastatic TNBC.
The results demonstrated encouraging preliminary objective response rates, suggesting the combination therapy may offer a new treatment avenue for this patient population. The findings have prompted researchers to initiate plans for a larger, randomized phase 3 trial to further assess the therapy's potential.
DISCUSSION (0)